DV
Dividend Vision

AVLN — Avalyn Pharma Inc.

Avalyn Pharma Inc. (AVLN)

Total return is 33.1% over the past 0.3 years, 24.8 points ahead of SPY at 8.3%.

Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, with a current pipeline focused on pulmonary fibrosis; its product candidates include AP01 and AP02, inhaled formulations of existing antifibrotic drugs, and AP03, a fixed-dose combination of two inhaled antifibiotics. As an early-stage biotech company, it does not currently distribute dividends. This security appeals to investors seeking exposure to clinical-stage pharmaceutical development, though it carries the significant risk inherent to pre-revenue companies in drug development.

AVLN key facts

Asset type
Stock
Asset class
Equity
Inception date
04/30/2026
Distribution frequency
None
Last close
$39.25
Market cap
$1,740,073,984
Average volume
193374.0
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.33